The Pathway of Let-7a-1/2-3p and HMGB1 Mediated Dexmedetomidine Inhibiting Microglia Activation in Spinal Cord Ischemia-Reperfusion Injury Mice

  • Ha sen ta na
  • Ming Nuo
  • Qing-tao Meng
  • Zhong-yuan XiaEmail author
Original Research


Microglial cell activation after spinal cord ischemia-reperfusion injury (SCIRI) commonly causes the secondary nerve motion function injury. This study aims to study the mechanism by which the drug dexmedetomidine (DEX) inhibits microglial cell activation and improves motion function of SCIRI mice. Mice SCIRI model was established, and microglia from spinal cord were isolated and cultured for subsequent molecule analysis of let-7a-1-3p, let-7a-2-3p, HMGB1, TNF-α, and IL-6. DEX was given by intraperitoneal injection. Mice motion function was evaluated by Basso mouse score. In vitro microglial cells were subjected to oxygen and glucose deprivation/reoxygenation (OGD/R) to imitate ischemia-reperfusion injury stimulation. DEX injection improves the mouse motion function in SCIRI model and upregulates let-7a-1/2-3p expression in the isolated activated microglia from SCIRI mice. In OGD/R-stimulated microglia, DEX treatment also caused the inactivation of cells, the upregulation of let-7a-1/2-3p expression, and the downregulation of HMGB1 expression. While the co-silencing of let-7a-1/2-3p in microglia in addition to DEX treatment restored the activation of microglia. HMGB1 is a targeted gene for let-7a-1/2-3p and negatively regulated by them. HMGB1 knockdown abrogates the pro-activation impact on microglial cell by let-7a-1/2-3p silencing. DEX inhibits the activation of microglial cell in the spinal cord of SCIRI mice, mediated by the let-7a-1/2-3p/HMGB1 pathway.


Let-7a-1/2-3p Dexmedetomidine Microglial cell Spinal cord ischemia-reperfusion injury 


Compliance with ethical standards

All protocols involved animals have been approved by the animal ethics committee of Renmin Hospital of Wuhan University.

Supplementary material

12031_2019_1338_Fig7_ESM.png (149 kb)

(PNG 149 kb)

12031_2019_1338_MOESM1_ESM.tif (115 kb)
High Resolution Image (TIF 115 kb)


  1. Anwar MA, Al Shehabi TS, Eid AH (2016) Inflammogenesis of secondary spinal cord injury. Front Cell Neurosci 10:98. CrossRefGoogle Scholar
  2. Aslan A, Cemek M, Eser O, Altunbaş K, Buyukokuroglu ME, Cosar M, Baş O, Ela Y, Fidan H (2009) Does dexmedetomidine reduce secondary damage after spinal cord injury? An experimental study. Eur Spine J 18:336–344. CrossRefGoogle Scholar
  3. Bao N, Fang B, Lv H, Jiang Y, Chen F, Wang Z, Ma H (2018) Upregulation of miR-199a-5p protects spinal cord against ischemia/reperfusion-induced injury via downregulation of ECE1 in rat. Cell Mol Neurobiol 38:1293–1303. CrossRefGoogle Scholar
  4. Bell MT, Agoston VA, Freeman KA, Puskas F, Herson PS, Mares J, Fullerton DA, Reece TB (2014) Interruption of spinal cord microglial signaling by alpha-2 agonist dexmedetomidine in a murine model of delayed paraplegia. J Vasc Surg 59:1090–1097. CrossRefGoogle Scholar
  5. Bell MT, Puskas F, Smith PD, Agoston VA, Fullerton DA, Meng X, Weyant MJ, Reece TB (2012a) Attenuation of spinal cord ischemia-reperfusion injury by specific α-2a receptor activation with dexmedetomidine. J Vasc Surg 56:1398–1402CrossRefGoogle Scholar
  6. Bell MT, Puskas F, Agoston VA, Cleveland JC, Freeman KA, Gamboni F, Herson PS, Meng X, Smith PD, Weyant MJ, Fullerton DA, Reece TB (2013) Toll-like receptor 4-dependent microglial activation mediates spinal cord ischemia-reperfusion injury. Circulation 128:S152–S156. CrossRefGoogle Scholar
  7. Bell MT, Puskas F, Smith PD, Agoston VA, Fullerton DA, Meng X, Weyant MJ, Reece TB (2012b) Attenuation of spinal cord ischemia-reperfusion injury by specific alpha-2a receptor activation with dexmedetomidine. J Vasc Surg 56:1398–1402. CrossRefGoogle Scholar
  8. Brites D, Fernandes A (2015) Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation. Front Cell Neurosci 9:476. CrossRefGoogle Scholar
  9. Celik F, Göçmez C, Kamaşak K, Tufek A, Guzel A, Tokgoz O, Fırat U, Evliyaoğlu O (2013) The comparison of neuroprotective effects of intrathecal dexmedetomidine and metilprednisolone in spinal cord injury. Int J Surg 11:414–418. CrossRefGoogle Scholar
  10. Cho KJ, Song J, Oh Y, Lee JE (2015) MicroRNA-let-7a regulates the function of microglia in inflammation. Mol Cell Neurosci 68:167–176. CrossRefGoogle Scholar
  11. Gurer B et al (2017) Comparative effects of vitamin D and methylprednisolone against ischemia/reperfusion injury of rabbit spinal cords. Eur J Pharmacol 813:50–60. CrossRefGoogle Scholar
  12. Li XQ, Cao XZ, Wang J, Fang B, Tan WF, Ma H (2014) Sevoflurane preconditioning ameliorates neuronal deficits by inhibiting microglial MMP-9 expression after spinal cord ischemia/reperfusion in rats. Mol Brain 7:69. CrossRefGoogle Scholar
  13. Liu K, Yan L, Jiang X, Yu Y, Liu H, Gu T, Shi E (2017) Acquired inhibition of microRNA-124 protects against spinal cord ischemia-reperfusion injury partially through a mitophagy-dependent pathway. J Thorac Cardiovasc Surg 154:1498–1508. CrossRefGoogle Scholar
  14. Miranda V, Sousa J, Mansilha A (2018) Spinal cord injury in endovascular thoracoabdominal aortic aneurysm repair: prevalence, risk factors and preventive strategies. Int Angiol 37:112–126. Google Scholar
  15. Nieto-Diaz M, Esteban FJ, Reigada D, Muñoz-Galdeano T, Yunta M, Caballero-López M, Navarro-Ruiz R, Águila Á, Maza RM (2014) MicroRNA dysregulation in spinal cord injury: causes, consequences and therapeutics. Front Cell Neurosci 8:53. CrossRefGoogle Scholar
  16. Paudel YN, Shaikh MF, Chakraborti A, Kumari Y, Aledo-Serrano Á, Aleksovska K, Alvim MKM, Othman I (2018) HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci 12:628. CrossRefGoogle Scholar
  17. Qiao Y, Peng C, Li J, Wu D, Wang X (2018) LncRNA MALAT1 is neuroprotective in a rat model of spinal cord ischemia-reperfusion injury through miR-204 regulation. Curr Neurovasc Res 15:211–219. CrossRefGoogle Scholar
  18. Rong H, Zhao Z, Feng J, Lei Y, Wu H, Sun R, Zhang Z, Hou B, Zhang W, Sun YE, Gu X, Ma Z, Liu Y (2017) The effects of dexmedetomidine pretreatment on the pro- and anti-inflammation systems after spinal cord injury in rats. Brain Behav Immun 64:195–207. CrossRefGoogle Scholar
  19. Shi Y, Guo X, Zhang J, Zhou H, Sun B, Feng J (2018) DNA binding protein HMGB1 secreted by activated microglia promotes the apoptosis of hippocampal neurons in diabetes complicated with OSA. Brain Behav Immun 73:482–492. CrossRefGoogle Scholar
  20. Smith PD, Bell MT, Puskas F, Meng X, Cleveland JC Jr, Weyant MJ, Fullerton DA, Reece TB (2013) Preservation of motor function after spinal cord ischemia and reperfusion injury through microglial inhibition. Ann Thorac Surg 95:1647–1653. CrossRefGoogle Scholar
  21. Sun Z, Zhao T, Lv S, Gao Y, Masters J, Weng H (2018) Dexmedetomidine attenuates spinal cord ischemia-reperfusion injury through both anti-inflammation and anti-apoptosis mechanisms in rabbits. J Transl Med 16:209. CrossRefGoogle Scholar
  22. Tan JA, Ho KM (2010) Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med 36:926–939. CrossRefGoogle Scholar
  23. Tian X, Liu C, Shu Z, Chen G (2017) Review: therapeutic targeting of HMGB1 in stroke. Curr Drug Deliv 14:785–790. CrossRefGoogle Scholar
  24. Zheng B, Zhang S, Ying Y, Guo X, Li H, Xu L, Ruan X (2018) Administration of Dexmedetomidine inhibited NLRP3 inflammasome and microglial cell activities in hippocampus of traumatic brain injury rats. Biosci Rep 38:BSR20180892. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of AnesthesiologyRenmin Hospital of Wuhan UniversityWuhanPeople’s Republic of China

Personalised recommendations